Lucid Diagnostics Inc. (LUCD)
| Market Cap | 156.79M +12.3% |
| Revenue (ttm) | 5.45M +24.9% |
| Net Income | -65.01M |
| EPS | -0.46 |
| Shares Out | 190.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,698,403 |
| Open | 0.9008 |
| Previous Close | 0.8968 |
| Day's Range | 0.8122 - 0.9150 |
| 52-Week Range | 0.8122 - 1.6290 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+387.15%) |
| Earnings Date | Aug 12, 2026 |
About LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in ... [Read more]
Financial Performance
In 2025, Lucid Diagnostics's revenue was $4.71 million, an increase of 8.28% compared to the previous year's $4.35 million. Losses were -$70.57 million, 33.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 387.15% from the latest price.
News
Lucid Diagnostics price target raised to $9.50 from $9.25 at Ascendiant
Ascendiant analyst Edward Woo raised the firm’s price target on Lucid Diagnostics (LUCD) to $9.50 from $9.25 and keeps a Buy rating on the shares following the Q2 report. The…
Lucid Diagnostics Slides: Corporate presentation
Lucid Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Lucid Diagnostics reports Q2 non-GAAP EPS (6c), consensus (5c)
Reports Q2 revenue $1.5M, consensus $1.43M. “Lucid’s commercial momentum strengthened throughout the second quarter and in recent weeks,” said CEO Lishan Aklog. “We continue to advance multiple commer...
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics s...
Lucid Diagnostics Earnings Call Transcript: Q2 2026
Q2 saw 2,770 tests and $1.5M revenue, up 17% sequentially, with strong progress in commercial coverage, VA engagement, and health system partnerships. Cash burn remained stable, and a positive Medicare LCD is anticipated, with further LBM and payer adoption expected.
Lucid Diagnostics Quarterly report: Q2 2026
Lucid Diagnostics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Lucid Diagnostics Earnings release: Q2 2026
Lucid Diagnostics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Lucid Diagnostics Slides: Q2 2026
Lucid Diagnostics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13...
Lucid Diagnostics Transcript: Canaccord Genuity's 46th Annual Growth Conference
A non-invasive molecular test for Barrett's Esophagus is gaining traction as a triage tool, with strong clinical evidence, high patient compliance, and growing commercial and VA engagement. Medicare coverage is pending, with substantial market potential and plans for rapid expansion once approved.
Lucid announces Concert issued positive coverage policy for EsoGuard test
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for n...
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the...
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed In...
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, op...
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagn...
Lucid Diagnostics Transcript: AGM 2026
The meeting confirmed a quorum and approved all proposals, including director re-elections, an increase in authorized shares, and auditor ratification. Attendees could submit questions, with responses to follow after the meeting.
Lucid Diagnostics Slides: Investor presentation
Lucid Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Lucid Diagnostics price target lowered to $2 from $3 at Maxim
Maxim lowered the firm’s price target on Lucid Diagnostics (LUCD) to $2 from $3 and keeps a Buy rating on the shares after its Q1 revenue missed estimates. The company…
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened ...
Lucid Diagnostics reports Q1 adjusted EPS (7c), consensus (6c)
Reports Q1 revenue $1.26M, consensus $1.38M. “Securing Medicare coverage remains our most important pending milestone, and our confidence in a positive outcome has not wavered,” said Lishan Aklog, M.D...
Lucid Diagnostics Earnings Call Transcript: Q1 2026
Q1 2026 saw 3,177 tests performed and $1.3M revenue, with cash runway extended into 2027 after a $16.8M offering. Medicare approval remains the key catalyst, while VA and commercial payer engagement is progressing, and first LBM coverage policy was secured.
Lucid Diagnostics Quarterly report: Q1 2026
Lucid Diagnostics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Lucid Diagnostics Earnings release: Q1 2026
Lucid Diagnostics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Lucid Diagnostics Slides: Q1 2026
Lucid Diagnostics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement miles...